Palvella Therapeutics, Inc. (PVLA)
| Market Cap | 215.67M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.75M |
| Shares Out | 11.22M |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,149 |
| Open | 18.97 |
| Previous Close | 19.00 |
| Day's Range | 18.05 - 19.64 |
| 52-Week Range | 6.20 - 22.32 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 40.33 (+109.83%) |
| Earnings Date | Mar 4, 2025 |
About PVLA
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is bas... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for PVLA stock is "Strong Buy." The 12-month stock price forecast is $40.33, which is an increase of 109.83% from the latest price.
News
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Expansion reflects Palvella's commitment to serving all patients affected by microcystic lymphatic malformations (microcystic LMs)
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating...